Competition will make weight-loss drugs better, cheaper and bigger
Novo Nordisk and Eli Lilly face a growing number of challengers
Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking remedies for erectile dysfunction and hair loss. Since May it has offered its own version of Wegovy, a blockbuster slimming jab, thanks to a quirk in American law that lets pharmacies replicate some brand-name drugs when there are shortages. Analysts expect that the company will pocket around $145m from its weight-loss drug this year.
This article appeared in the Business section of the print edition under the headline “Pharma frenzy”
Business October 26th 2024
- America’s growing profits are under threat
- Are bosses right to insist that workers return to the office?
- South-East Asia’s stodgy conglomerates are holding it back
- Competition will make weight-loss drugs better, cheaper and bigger
- Memory chips could be the next bottleneck for AI
- How to manage politics in the workplace
- Can Google or Huawei stymie Apple’s march towards $4trn?
More from Business
TikTok’s time is up. Can Donald Trump save it?
The imperilled app hopes for help from an old foe
The UFC, Dana White and the rise of bloodsport entertainment
There is more to the mixed-marital-arts impresario than his friendship with Donald Trump
Will Elon Musk scrap his plan to invest in a gigafactory in Mexico?
Donald Trump’s return to the White House may have changed Tesla’s plans
Germany is going nuts for Dubai chocolate
Will the hype last?
The year ahead: a message from the CEO
From the desk of Stew Pidd
One of the biggest energy IPOs in a decade could be around the corner
Venture Global, a large American gas exporter, is going public